YDES

TAIPEI, Taiwan, April 30, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced its financial results for the full year ended December 31, 2025. Management Commentary “2025 was a highly transformative and foundational year for YD Bio, characterized by the successful capitalization of our long-term strategic vision. The successful completion of our business combination with Breeze Holdings Acquisition Corp. in August 2025, alongside a $13.2 million private investment in public equity (PIPE) financing, helped to significantly strengthen our balance sheet. Furthermore, we achieved a 17% increase in net revenue, driven predominantly by expanded pharmaceutical sales volumes and strategic new product launches,” said Dr. Ethan Shen, Chairman and CEO of YD Bio. “We ended the year well-capitalized with approximately $6.0 million in cash and cash equivalents, which we believe positions us to securely meet our operating obligations in 2026 and aggressively pursue our clinical milestones.” “During the past year, we consciously increased our research and development expenditures by approximately $1.1 million to secure essential licensed patents and technological know-how, and we restructured our sales mix to rapidly scale our commercial footprint. These foundational investments in our clinical service infrastructure and diagnostics platform are designed to support robust growth across multiple regulated healthcare segments.” “Looking ahead, our strategic focus for 2026 is to aggressively advance our proprietary assets from validation toward expanded regulatory and commercial execution. We have already achieved certain milestones in our therapeutics pipeline by completing comprehensive Chemistry, Manufacturing, and Controls (CMC) development and filing Drug Master Files (DMFs) with the U.S. Food and Drug Administration (FDA) for our Limbal Stem Cell (LSC) platform and derived exosome products. This paves the way for us to submit Investigational New Drug (IND) applications to the FDA for both Dry Eye Disease and Age-Related Macular Degeneration in 2026. Concurrently, we are advancing our OkaiDx™ Pancreatic Cancer Early Detection Program toward an FDA Q-Submission to discuss potential Breakthrough Device eligibilit...

TAIWAN, Sept. 30, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio Ltd” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced its unaudited financial results for the six months ended June 30, 2025. Management Commentary “With the closing of our business combination with Breeze Holdings Acquisition Corp. (“Breeze Holdings’) in August and the concurrent closing of a private investment in public equity financing, securing $13.2 million in gross proceeds to support our wholly-owned subsidiary YD Biopharma Limited (“YD Biopharma”)’s liquidity and capital resources, we are now a publicly traded biotech platform with the capital and structure needed to accelerate innovation,” said Dr. Ethan Shen, Chairman of the Board and CEO of YD Bio Ltd. “Despite a slight decrease in net revenue, we managed to continue investing in general and administrative functions and R&D to expand capacity. We also advanced two licensed patents to execute growth strategy during the reporting period.” “Our vision remains to deliver minimally invasive, early cancer detection globally and pioneer regenerative ophthalmology therapies. As previously announced, through exclusive licensing with EG BioMed Co., Ltd. (“EG BioMed”), we’ve launched a DNA methylation-based pancreatic cancer screening LDT and will introduce a breast cancer recurrence monitoring LDT later this year. In partnership with 3D Global Biotech Inc. (“3D Global”), we are preparing corneal stem-cell and exosome-based treatments for dry eye, glaucoma and corneal injury, with clinical trials slated for 2027. Simultaneously, our proven track record as a supplier of investigational drugs and ancillary materials underpins a robust clinical-trial services business.” “We believe YD Bio Limited is positioned to capture a share of the multibillion-dollar oncology diagnostics, ocular therapeutics and clinical-trial services markets. Our strengthened balance sheet, public-market profile and diversified pipeline set the stage for sustainable revenue growth, margin expansion and long-term value creation for patients, partners and shareholders,” Dr. Shen said. YD Biopharma’s Half Year 2025 Financial Results YD Biopharma’s vision is to deliver early cancer detection globally, offering patients additional less invasive treatment options...